We are live on ! Find out more
ETNB

89bio

Delisted

ETNB was delisted on the 29th of October, 2025.

145 hedge funds and large institutions have $1.08B invested in 89bio in 2023 Q1 according to their latest regulatory filings, with 60 funds opening new positions, 48 increasing their positions, 29 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 60 | Existing positions closed: 20

122% more call options, than puts

Call options by funds: $55.5M | Put options by funds: $25M

84% more capital invested

Capital invested by funds: $589M → $1.08B (+$492M)

66% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 29

37% more funds holding

Funds holding: 106145 (+39)

3.15% more ownership

Funds ownership: 99.5%102.65% (+3.2%)

Holders
145
Holders Change
+39
Holders Change %
+36.79%
% of All Funds
2.31%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.05%
New
60
Increased
48
Reduced
29
Closed
20
Calls
$55.5M
Puts
$25M
Net Calls
+$30.5M
Net Calls Change
+$25.5M
Name Holding Trade Value Shares
Change
Change in
Stake
Franklin Resources
26
Franklin Resources
California
$10.8M +$9.27M +710,832 New
Susquehanna International Group
27
Susquehanna International Group
Pennsylvania
$9.81M +$5.38M +412,851 +179%
EAM
28
Eventide Asset Management
Massachusetts
$9.78M +$8.37M +642,073 New
Voloridge Investment Management
29
Voloridge Investment Management
Florida
$8.75M +$6.8M +521,740 +984%
OCM
30
Orchard Capital Management
Illinois
$8.41M
Bank of America
31
Bank of America
North Carolina
$8.29M +$410K +31,465 +6%
JP Morgan Chase
32
JP Morgan Chase
New York
$8.13M +$5.09M +390,176 +271%
Geode Capital Management
33
Geode Capital Management
Massachusetts
$7.68M +$2.09M +160,089 +47%
AG
34
Artal Group
Luxembourg
$7.62M +$1.3M +100,000 +25%
Alkeon Capital Management
35
Alkeon Capital Management
New York
$7.62M +$6.52M +500,000 New
SCM
36
Soleus Capital Management
Connecticut
$7.52M +$1.5M +115,000 +30%
Goldman Sachs
37
Goldman Sachs
New York
$7.13M -$2.5M -191,733 -29%
SCM
38
Silverarc Capital Management
Massachusetts
$6.67M +$5.71M +438,215 New
LCM
39
Laurion Capital Management
New York
$6.65M +$3.26M +249,785 +134%
OCA
40
Octagon Capital Advisors
New York
$6.09M +$261K +20,000 +5%
Citigroup
41
Citigroup
New York
$5.84M -$2.02M -155,091 -29%
SSA
42
Schonfeld Strategic Advisors
New York
$5.38M -$1.65M -126,797 -26%
Alyeska Investment Group
43
Alyeska Investment Group
Illinois
$5.08M +$4.35M +333,485 New
Rafferty Asset Management
44
Rafferty Asset Management
New York
$4.87M +$4.17M +319,498 New
DCM
45
Driehaus Capital Management
Illinois
$4.59M +$3.93M +301,581 New
EI
46
EAM Investors
California
$4.36M +$137K +10,477 +4%
CM
47
Caption Management
Oklahoma
$3.97M +$3.4M +260,638 New
Ameriprise
48
Ameriprise
Minnesota
$3.84M +$3.29M +251,984 New
GPP
49
Great Point Partners
Connecticut
$3.81M +$3.26M +250,000 New
PHP
50
Parkman Healthcare Partners
Connecticut
$3.76M -$1.12M -85,924 -26%

ETNB Hedge Fund Activity: Q1 2023 in Review

145 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in 89bio (ETNB) for Q1 2023, worth a combined $1.08B — up 84% from $589M a quarter earlier.

Buyers outnumbered sellers: 60 funds opened new ETNB positions and 20 closed out — a net gain of 40 holders — while 48 added to existing stakes and 29 trimmed.

The largest buyer was State Street, adding an estimated $38.7M. The largest seller was OrbiMed, exiting entirely with an estimated $46.6M sold.

  • 145 institutional investors held 89bio (ETNB) as of Q1 2023, up from 106 in Q4 2022.
  • Funds reported $1.08B of 89bio stock for Q1 2023, up 84% quarter-over-quarter.
  • 60 funds opened new 89bio positions in Q1 2023 and 20 closed out, a net change of +40 holders.
  • The largest 89bio buyer in Q1 2023 was State Street, an estimated $38.7M added.
  • The largest 89bio seller in Q1 2023 was OrbiMed, an estimated $46.6M sold.

Based on aggregated 13F filings for Q1 2023.